- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06422546
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC (pre-FLAME)
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers After Three Weeks of Osimertinib Targeted Therapy in Chinese Patients With Stage IIIB ,IIIC ,or IV Metastatic or Recurrent Non Squamous EGFR-positive Non-small Cell Lung Cancer
A prospective ,multicenter ,non-interventional ,real-world study observing changes in molecular markers after three weeks of osimertinib targeted therapy in EGFRm NSCLC
Studieoversikt
Status
Forhold
Detaljert beskrivelse
A prospective ,multicenter ,non-interventional ,real-world study observing changes in molecular markers after three weeks of osimertinib targeted therapy in Chinese patients with stage IIIB ,IIIC ,or IV metastatic or recurrent non squamous EGFR-positive non-small cell lung cancer
Studietype
Registrering (Antatt)
Kontakter og plasseringer
Studiesteder
-
-
-
Beijing, Kina
- Rekruttering
- Cancer Hospital Chinese
-
Ta kontakt med:
- Jie Wang
- Telefonnummer: 13910704669
- E-post: zlhuxi@163.com
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
stage IIIB,IIIC,IV or recurrent NSCLC
Beskrivelse
Inclusion Criteria:
- Male or female,age ≥18 years.
- Newly diagnosed,histologically confirmed,and classified as stage IIIB,IIIC,IV or recurrent NSCLC which are not amenable to curative surgery or radiotherapy .
- No prior systemic antitumor therapy, including EGFR -TKIs or immunotherapy .
- Presence of an EGFR mutation confirmed by a local laboratory in blood or tissue samples .
- Adequate blood samples available for molecular testing .
- Provision of written informed consent .
Exclusion Criteria:
- Inability to provide plasma samples at baseline .
- Baseline blood EGFR mutation status not confirmed by the central laboratory .
- Refusal to receive subsequent treatment with osimertinib .
- Any condition that ,in the investigator's judgment ,could interfere with study procedures or confound outcome assessment .
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
To describe the characteristics of EGFR mutation changes at baseline and after 3 weeks of osimertinib treatment
Tidsramme: baseline and after three weeks of osimertinib treatment
|
Baseline plasma ctDNA EGFR mutation status and mutation types will be obtained through the SuperARMS assay ,as well as the ctDNA EGFR clearance status three weeks after treatment . |
baseline and after three weeks of osimertinib treatment
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
To evaluate the changes in EGFR mutations at baseline and after 3weeks treatment,and their correlation with the therapeutic efficacy of osimertinib
Tidsramme: baseline and after three weeks of osimertinib treatment
|
Correlation between the clearance of EGFR sensitive mutations and PFS was monitored using the SuperARMS method Note:PFS is defined according to RECIST v1 .1 and assessed by the investigator . |
baseline and after three weeks of osimertinib treatment
|
Samarbeidspartnere og etterforskere
Samarbeidspartnere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- pre-FLAME
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .